Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Hepatology ; 67(5): 1931-1942, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29194678

RESUMEN

In patients with acute liver failure (ALF), elevated prothrombin time and thrombocytopenia can fuel a perception of a bleeding tendency. However, the incidence, site, risk factors, and clinical significance of bleeding complications have not been quantified in a large cohort of patients with ALF. We studied 1,770 adult patients enrolled in the ALF Study Group Registry between 1998 and 2016. Bleeding complications and blood component transfusions were collected for 7 days after admission. The relationship of bleeding complications to 21-day mortality was assessed. Despite a median international normalized ratio of 2.7 and platelet count of 96 × 109 /L on admission, bleeding complications were observed in only 187 patients (11%), including 173 spontaneous and 22 postprocedural bleeding episodes. Eighty-four percent of spontaneous bleeding episodes were from an upper gastrointestinal source and rarely resulted in red blood cell transfusion. Twenty patients experienced an intracranial bleed; half of these occurred spontaneously and half after intracranial pressure monitor placement, and this was the proximate cause of death in 20% and 50%, respectively. Bleeders and patients who received red blood cell transfusions were more acutely ill from extrahepatic organ system failure but not from hepatocellular failure. Consistent with this observation, bleeding complications were associated with lower platelet counts but not higher international normalized ratio. Transfusion of any blood component was associated with nearly 2-fold increased death or need for liver transplantation at day 21, but bleeding complications were the proximate cause of death in only 5% of cases. CONCLUSIONS: Despite a perceived bleeding diathesis, clinically significant bleeding is uncommon in patients with ALF; bleeding complications in patients with ALF are markers of severe systemic inflammation rather than of coagulopathy and so portend a poor prognosis. (Hepatology 2018;67:1931-1942).


Asunto(s)
Hemorragia/etiología , Fallo Hepático Agudo/complicaciones , Adulto , Coagulación Sanguínea , Trastornos de la Coagulación Sanguínea/complicaciones , Transfusión Sanguínea/estadística & datos numéricos , Femenino , Hemorragia/epidemiología , Hemorragia/terapia , Humanos , Incidencia , Fallo Hepático Agudo/mortalidad , Masculino , Persona de Mediana Edad , Monitoreo Fisiológico/métodos , Sistema de Registros , Análisis de Supervivencia
2.
J Pain Symptom Manage ; 61(3): 474-487, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-32889040

RESUMEN

CONTEXT: Sickle cell disease (SCD), an autosomal recessive blood disorder, affects millions of people worldwide. Approximately 80% of all cases are located in Africa. OBJECTIVES: This cross-national, interdisciplinary, collaborative study investigated provider attitudes about, and practices for, managing (assessing and treating) SCD pain. METHODS: We conducted 111 quantitative surveys and 52 semistructured interviews with health-care providers caring for adults and/or children with SCD in Cameroon, Jamaica, and the U.S. RESULTS: Applying Haywood's scale for assessing SCD provider attitudes, the Jamaica site scored lower on "Negative Attitudes" than the Cameroonian and U.S. sites (P = 0.03 and <0.001, respectively). Providers at the U.S. site scored lower on "Positive Attitudes" than other sites (P < 0.001). "Red Flag" scores at the Cameroon sites were lower than at other sites (P < 0.001). Qualitative results across all three sites describe the current practices for SCD pain management, as well as the challenges surrounding management for health providers, including pain subjectivity, patient-provider and parent-provider relationships, resource availability, perceptions of drug-seeking behavior, and adherence. Providers also spontaneously offered solutions to reported challenges. CONCLUSION: Overall, findings reveal that SCD provider attitudes toward their patients differed across sites, yet at all three sites, treating SCD pain is multidimensional.


Asunto(s)
Anemia de Células Falciformes , Manejo del Dolor , Adulto , África , Anemia de Células Falciformes/terapia , Actitud del Personal de Salud , Niño , Humanos , Dolor
3.
PRiMER ; 4: 35, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33426484

RESUMEN

COVID-19 has altered clinical clerkships for medical students, providing an opportunity for telehealth with medical students to take center stage in the age of technology. This research brief demonstrates why and how to incorporate medical students into telehealth. For the purposes of clinical students, telehealth is a better educational alternative to in-person patient care than online modules. We performed a successful outpatient family medicine telehealth pilot program at the Medical University of South Carolina (MUSC) that is currently being scaled up to other clerkships. This pilot was very limited in scope, but serves as a scalable model for future telehealth programs and curricula incorporating medical students.

4.
Invest Ophthalmol Vis Sci ; 58(14): 6489-6499, 2017 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-29288267

RESUMEN

Purpose: This study examines the role of PI3K/Akt pathway in δ-opioid receptor agonist (SNC-121)-induced RGC neuroprotection in a chronic glaucoma rat model. Methods: Injecting hypertonic saline into the limbal veins of Brown Norway rats elevated IOP. Rats were treated either with 1 mg/kg SNC-121 or 3 mg/kg 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY-294002; PI3K/Akt inhibitor) plus SNC-121 once daily for 7 days. Pattern ERGs were recorded in response to contrast reversal of patterned visual stimuli. Retinal ganglion cells (RGC) were visualized by Fluorogold retrograde labeling. Optic nerve head (ONH) astrocytes were pretreated with PI3K/Akt inhibitors for 30 minutes followed by 1-µM SNC-121 treatment. Changes in matrix metalloproteinases (MMP-1, -2, and -3) production and PI3K/Akt activation in optic nerve and TNF-α treated ONH astrocytes were measured by immunohistochemistry and Western blotting. Results: SNC-121 activates the PI3K/Akt pathway in ONH astrocytes and the retina. In ONH astrocytes, SNC-121-induced Akt activation was fully inhibited by PI3K/Akt inhibitors. A sustained decline (7-42 days post injury) in Akt activation was seen in the ocular-hypertensive retina and optic nerve. This decline is reversed to normal levels by 1-mg/kg intraperitoneally (i.p.) SNC-121 treatment. Both pattern ERG amplitudes and RGC numbers were reduced in ocular hypertensive eyes, which were significantly increased in SNC-121-treated animals. Interestingly, SNC-121-induced increase in pattern-ERG amplitudes and RGC numbers were inhibited in LY-294002 pretreated animals. Additionally, SNC-121 treatment inhibited MMP-1, -2, and -3 production from the optic nerve of ocular hypertensive rats and TNF-α-treated ONH astrocytes. Conclusions: PI3K/Akt pathway plays a crucial role in SNC-121-mediated RGC neuroprotection against glaucomatous injury.


Asunto(s)
Glaucoma/complicaciones , Neuroprotección/efectos de los fármacos , Proteínas Proto-Oncogénicas c-akt/genética , Receptores Opioides delta/metabolismo , Enfermedades de la Retina/prevención & control , Animales , Astrocitos/metabolismo , Astrocitos/patología , Benzamidas/farmacología , Western Blotting , Células Cultivadas , Enfermedad Crónica , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Electrorretinografía , Glaucoma/genética , Glaucoma/metabolismo , Inmunohistoquímica , Masculino , Disco Óptico , Nervio Óptico , Piperazinas/farmacología , Proteínas Proto-Oncogénicas c-akt/efectos de los fármacos , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ratas , Ratas Endogámicas BN , Receptores Opioides delta/agonistas , Enfermedades de la Retina/metabolismo , Enfermedades de la Retina/patología , Células Ganglionares de la Retina/metabolismo
5.
J AAPOS ; 19(5): 441-4, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26486026

RESUMEN

BACKGROUND: The Spot Vision Screener has demonstrated good sensitivity and specificity in the pediatric ophthalmology clinic setting. We sought to evaluate the updated Spot (version 2.0.16) in a general pediatric population through a collaboration of the Storm Eye Institute of the Medical University of South Carolina, the Clinica Dr Clorito Picado, and National Children's Hospital of Costa Rica. We compared results of screening with the Spot and pediatric ophthalmologic examination and determined sensitivity and specificity of the Spot in detecting amblyogenic risk factors (ARFs) according to the 2013 AAPOS Vision Screening Committee guidelines for automated vision screeners. METHODS: Children were screened with the Spot followed by a pediatric ophthalmologic examination. Cycloplegic refraction and motility findings were analyzed by age group to determine ARFs. RESULTS: A total of 219 subjects, averaging 60 months of age (range, 20-119 mo) were included. The prevalence of ARFs in our population was 12.3% (27/219). The most common risk factor was astigmatism, with a prevalence of 8.7% (19/219). The Spot referred 43 children (19.6%). Sensitivity of the Spot was 92.6%; specificity, 90.6%. The positive predictive value was 58.1%; the negative predictive value, 98.9%. CONCLUSIONS: The Spot demonstrated good sensitivity and specificity in detecting amblyopia risk factors in this general pediatric population.


Asunto(s)
Ambliopía/diagnóstico , Selección Visual/instrumentación , Ambliopía/epidemiología , Niño , Preescolar , Costa Rica/epidemiología , Reacciones Falso Positivas , Femenino , Humanos , Lactante , Masculino , Valor Predictivo de las Pruebas , Prevalencia , Estudios Prospectivos , Retinoscopía , Factores de Riesgo , Sensibilidad y Especificidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA